Amir Shojaei

Amir Shojaei currently serves as the Chief Scientific Officer at Harrow since January 2025 and as a Board Member at iVeena. Previously, Amir held significant roles including Executive Board Member at ForwardVue Pharma, Chief Scientific Officer and EVP-Clinical Development at AsclepiX Therapeutics, CEO at TherOptix, and Chief Development Officer at TearClear. Amir's expertise in ophthalmology includes leadership roles at Novartis and Takeda, as well as a longstanding tenure at Shire in global clinical development. Amir co-founded SIDE Pharmaceuticals, LLC, and possesses advanced degrees in Pharmaceutical Sciences and Pharmacy from the University of the Pacific, along with a Bachelor of Science in Biological Sciences from the University of Alberta.